Loading...

Vimta Labs

NSEI:VIMTALABS
Snowflake Description

Excellent balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VIMTALABS
NSEI
₹4B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Vimta Labs Limited provides contract research and testing services in India and internationally. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
VIMTALABS Share Price and Events
7 Day Returns
-2.4%
NSEI:VIMTALABS
-0.4%
IN Life Sciences
-2.2%
IN Market
1 Year Returns
-22.7%
NSEI:VIMTALABS
27.5%
IN Life Sciences
-3.1%
IN Market
VIMTALABS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vimta Labs (VIMTALABS) -2.4% -10% -15.8% -22.7% 73.1% 54.9%
IN Life Sciences -0.4% 2.7% -4.6% 27.5% 42.2% 114%
IN Market -2.2% -2.7% -4.1% -3.1% 22.1% 34.8%
1 Year Return vs Industry and Market
  • VIMTALABS underperformed the Life Sciences industry which returned 27.5% over the past year.
  • VIMTALABS underperformed the Market in India which returned -3.1% over the past year.
Price Volatility
VIMTALABS
Industry
5yr Volatility vs Market

Value

 Is Vimta Labs undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Vimta Labs to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Vimta Labs.

NSEI:VIMTALABS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 16.5%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NSEI:VIMTALABS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.02
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.023 (1 + (1- 35%) (6.9%))
1.046
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.05
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (1.046 * 8.6%)
16.55%

Discounted Cash Flow Calculation for NSEI:VIMTALABS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Vimta Labs is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NSEI:VIMTALABS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 16.55%)
2020 91.68 Est @ 16.08% 78.66
2021 104.08 Est @ 13.52% 76.62
2022 116.28 Est @ 11.73% 73.45
2023 128.46 Est @ 10.48% 69.62
2024 140.79 Est @ 9.6% 65.47
2025 153.44 Est @ 8.98% 61.22
2026 166.56 Est @ 8.55% 57.02
2027 180.31 Est @ 8.25% 52.96
2028 194.81 Est @ 8.04% 49.10
2029 210.19 Est @ 7.89% 45.45
Present value of next 10 years cash flows ₹629.58
NSEI:VIMTALABS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= ₹210.19 × (1 + 7.55%) ÷ (16.55% – 7.55%)
₹2,512.21
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹2,512.21 ÷ (1 + 16.55%)10
₹543.24
NSEI:VIMTALABS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹629.58 + ₹543.24
₹1,172.82
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹1,172.82 / 22.11
₹53.05
NSEI:VIMTALABS Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in NSEI:VIMTALABS represents 0.99939x of BSE:524394
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99939x
Value per Share
(Listing Adjusted, INR)
= Value per Share (INR) x Listing Adjustment Factor
= ₹ 53.05 x 0.99939
₹53.02
Value per share (INR) From above. ₹53.02
Current discount Discount to share price of ₹164.90
= -1 x (₹164.90 - ₹53.02) / ₹53.02
-211%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Vimta Labs is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vimta Labs's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vimta Labs's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:VIMTALABS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in INR ₹11.45
BSE:524394 Share Price ** BSE (2019-07-15) in INR ₹165
India Life Sciences Industry PE Ratio Median Figure of 7 Publicly-Listed Life Sciences Companies 30.41x
India Market PE Ratio Median Figure of 2,834 Publicly-Listed Companies 14.88x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vimta Labs.

NSEI:VIMTALABS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:524394 Share Price ÷ EPS (both in INR)

= 165 ÷ 11.45

14.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vimta Labs is good value based on earnings compared to the IN Life Sciences industry average.
  • Vimta Labs is good value based on earnings compared to the India market.
Price based on expected Growth
Does Vimta Labs's expected growth come at a high price?
Raw Data
NSEI:VIMTALABS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 14.41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
-5.6%per year
Asia Life Sciences Industry PEG Ratio Median Figure of 7 Publicly-Listed Life Sciences Companies 2.03x
India Market PEG Ratio Median Figure of 534 Publicly-Listed Companies 1.29x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vimta Labs, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vimta Labs's assets?
Raw Data
NSEI:VIMTALABS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in INR ₹77.60
BSE:524394 Share Price * BSE (2019-07-15) in INR ₹165
India Life Sciences Industry PB Ratio Median Figure of 10 Publicly-Listed Life Sciences Companies 1.81x
India Market PB Ratio Median Figure of 3,668 Publicly-Listed Companies 0.96x
NSEI:VIMTALABS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:524394 Share Price ÷ Book Value per Share (both in INR)

= 165 ÷ 77.60

2.13x

* Primary Listing of Vimta Labs.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vimta Labs is overvalued based on assets compared to the IN Life Sciences industry average.
X
Value checks
We assess Vimta Labs's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Vimta Labs has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Vimta Labs expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Vimta Labs, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-5.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vimta Labs expected to grow at an attractive rate?
  • Vimta Labs's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Vimta Labs's earnings are expected to decrease over the next 1-3 years, this is below the India market average.
  • Unable to compare Vimta Labs's revenue growth to the India market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NSEI:VIMTALABS Future Growth Rates Data Sources
Data Point Source Value (per year)
NSEI:VIMTALABS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts -5.6%
India Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 16.1%
Asia Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 23.4%
India Market Earnings Growth Rate Market Cap Weighted Average 17%
India Market Revenue Growth Rate Market Cap Weighted Average 9.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:VIMTALABS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:VIMTALABS Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
NSEI:VIMTALABS Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2019-03-31 2,130 391 253
2018-12-31 2,126 236
2018-09-30 2,071 245
2018-06-30 1,970 218
2018-03-31 1,836 334 164
2017-12-31 1,693 134
2017-09-30 1,602 104
2017-06-30 1,552 83
2017-03-31 1,538 239 106
2016-12-31 1,468 94
2016-09-30 1,376 74
2016-06-30 1,344 79

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Vimta Labs's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if Vimta Labs is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:VIMTALABS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Vimta Labs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:VIMTALABS Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
NSEI:VIMTALABS Past Financials Data
Date (Data in INR Millions) EPS *
2019-03-31 11.45
2018-12-31 10.68
2018-09-30 11.06
2018-06-30 9.87
2018-03-31 7.43
2017-12-31 6.04
2017-09-30 4.71
2017-06-30 3.73
2017-03-31 4.79
2016-12-31 4.28
2016-09-30 3.37
2016-06-30 3.56

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vimta Labs will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Vimta Labs's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vimta Labs has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Vimta Labs performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vimta Labs's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vimta Labs has delivered over 20% year on year earnings growth in the past 5 years.
  • Vimta Labs's 1-year earnings growth exceeds its 5-year average (54% vs 27.6%)
  • Vimta Labs's earnings growth has not exceeded the IN Life Sciences industry average in the past year (54% vs 54%).
Earnings and Revenue History
Vimta Labs's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vimta Labs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:VIMTALABS Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 2,129.76 253.11 665.36
2018-12-31 2,126.47 236.10 665.95
2018-09-30 2,071.36 244.65 645.58
2018-06-30 1,969.82 218.30 621.44
2018-03-31 1,836.19 164.33 594.57
2017-12-31 1,693.49 133.64 562.03
2017-09-30 1,602.18 104.13 547.76
2017-06-30 1,551.96 82.61 533.87
2017-03-31 1,538.48 105.92 503.04
2016-12-31 1,468.09 94.49 460.07
2016-09-30 1,376.24 74.49 433.05
2016-06-30 1,343.55 78.81 349.44
2016-03-31 1,247.09 64.34 381.94
2015-12-31 1,202.15 62.95 485.94
2015-09-30 1,157.19 59.48 475.13
2015-06-30 1,068.05 44.74 315.73
2015-03-31 1,072.72 50.62 343.30
2014-12-31 1,081.90 52.19 476.67
2014-09-30 1,140.43 85.18 465.89
2014-06-30 1,195.34 113.51 454.84
2014-03-31 1,183.16 132.39 443.02
2013-12-31 1,175.11 130.24 395.04
2013-09-30 1,130.44 104.23 387.92
2013-06-30 1,101.47 74.73 381.56
2013-03-31 1,091.03 42.13 410.08
2012-12-31 1,029.80 -41.63 373.92
2012-09-30 965.93 -91.69 374.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Vimta Labs has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Vimta Labs used its assets more efficiently than the IN Life Sciences industry average last year based on Return on Assets.
  • Vimta Labs has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Vimta Labs's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vimta Labs has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Vimta Labs's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vimta Labs's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vimta Labs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vimta Labs's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vimta Labs's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vimta Labs Company Filings, last reported 3 months ago.

NSEI:VIMTALABS Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 1,715.52 258.26 26.67
2018-12-31 1,597.86 291.18 27.53
2018-09-30 1,597.86 291.18 27.53
2018-06-30 1,520.53 399.55 19.95
2018-03-31 1,520.53 399.38 19.95
2017-12-31 1,412.71 371.81 16.48
2017-09-30 1,412.71 371.81 16.48
2017-06-30 1,361.48 435.71 12.56
2017-03-31 1,361.48 434.90 6.25
2016-12-31 1,308.58 334.56 32.37
2016-09-30 1,308.58 334.56 32.37
2016-06-30 1,261.03 259.73 34.71
2016-03-31 1,261.03 258.93 34.71
2015-12-31 1,260.70 61.42 16.11
2015-09-30 1,260.70 61.42 16.11
2015-06-30 1,223.30 35.06 10.22
2015-03-31 1,223.30 35.06 10.22
2014-12-31 1,227.75 38.54 14.92
2014-09-30 1,227.75 38.54 14.92
2014-06-30 1,203.88 65.61 39.09
2014-03-31 1,203.88 65.61 39.09
2013-12-31 1,198.97 80.74 14.26
2013-09-30 1,198.97 80.74 14.26
2013-06-30 1,123.21 116.32 18.48
2013-03-31 1,123.21 116.32 18.48
2012-12-31 1,110.16 120.29 12.94
2012-09-30 1,110.16 120.29 12.94
  • Vimta Labs's level of debt (15.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (5.4% vs 15.1% today).
  • Debt is well covered by operating cash flow (151.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 16.2x coverage).
X
Financial health checks
We assess Vimta Labs's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vimta Labs has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Vimta Labs's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.21%
Current annual income from Vimta Labs dividends.
If you bought ₹2,000 of Vimta Labs shares you are expected to receive ₹24 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Vimta Labs's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.56%).
  • Vimta Labs's dividend is below the markets top 25% of dividend payers in India (2.17%).
Upcoming dividend payment

Purchase Vimta Labs before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:VIMTALABS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Asia Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 0.8%
India Market Average Dividend Yield Market Cap Weighted Average of 1447 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.6%
India Top 25% Dividend Yield 75th Percentile 2.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:VIMTALABS Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
NSEI:VIMTALABS Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2019-07-03 2.000 1.152
2019-05-13 2.000 1.080
2018-08-01 2.000 0.829
2018-05-11 2.000 0.945
2018-01-31 0.000 0.000
2017-12-01 0.000 0.000
2017-08-17 0.000 0.000
2016-08-08 1.000 0.901
2016-05-16 1.000 1.292
2015-08-21 1.000 1.308
2014-07-07 2.000 2.591
2013-05-31 0.600 1.478
2013-02-04 0.000 0.000
2012-11-05 0.000 0.000
2012-08-22 0.000 0.000
2012-05-21 0.000 0.000
2011-09-26 0.400 2.442
2010-10-13 0.800 2.950
2009-06-01 0.800 2.611
2009-04-28 0.800 2.975

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Vimta Labs's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (5.7x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vimta Labs's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vimta Labs afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vimta Labs has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Vimta Labs's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Harita Vasireddi
COMPENSATION ₹12,430,000
AGE 45
TENURE AS CEO 6 years
CEO Bio

Ms. Harita Vasireddi has been the Managing Director of Vimta Labs Ltd. since July 15, 2013 and serves as its Whole Time Director. She was a Member of Scientific Advisory Board at Vimta Labs Ltd. Ms. Vasireddi served as the Joint Managing Director of Vimta Labs Ltd., from May 25, 2012 to July 15, 2013. Ms. Vasireddi served as a Director of Quality at Vimta Labs Ltd., until May 25, 2012 and joined it on April 1, 2005. Ms. Vasireddi served as a Director for Projects at Vimta Labs Ltd. She serves as an Executive (USA) in Service Operations Management. She served at Vimta Rosiest (P) Ltd. as Manager Operations for four years. She is a Pharmacist. Ms. Harita holds a Bachelor of Pharmaceutical Sciences degree from Mysore University, India and an MBA in Operations Management from Boston College, USA.

CEO Compensation
  • Harita's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Harita's remuneration is higher than average for companies of similar size in India.
Management Team Tenure

Average tenure and age of the Vimta Labs management team in years:

3.5
Average Tenure
43
Average Age
  • The tenure for the Vimta Labs management team is about average.
Management Team

Harita Vasireddi

TITLE
MD & Whole Time Director
COMPENSATION
₹12M
AGE
45
TENURE
6 yrs

Amit Pathak

TITLE
Chief Financial Officer
AGE
39
TENURE
0.5 yrs

V. Vungal

TITLE
Executive Director of Operations & Executive Director
COMPENSATION
₹12M
AGE
68
TENURE
6 yrs

Sujani Vasireddi

TITLE
GM of Commercial
AGE
43
TENURE
0.9 yrs

Srinivas Puppala

TITLE
Vice President of Human Resources
TENURE
0.5 yrs

Satya Neerukonda

TITLE
Senior VP & Global Head of Business Development
AGE
43
TENURE
4.5 yrs

Jagadeesh Kodali

TITLE
Head of Food Division & Associate VP of Food Division
TENURE
3.5 yrs
Board of Directors Tenure

Average tenure and age of the Vimta Labs board of directors in years:

0.2
Average Tenure
66
Average Age
  • The average tenure for the Vimta Labs board of directors is less than 3 years, this suggests a new board.
Board of Directors

Sivalinga Vasireddi

TITLE
Non Executive Chairman
COMPENSATION
₹4M
AGE
71

Harita Vasireddi

TITLE
MD & Whole Time Director
COMPENSATION
₹12M
AGE
45
TENURE
14.3 yrs

V. Vungal

TITLE
Executive Director of Operations & Executive Director
COMPENSATION
₹12M
AGE
68

Yalamanchili Rani

TITLE
Independent Director
COMPENSATION
₹130K
AGE
66
TENURE
1.6 yrs

Kanury Rao

TITLE
Member of Scientific Advisory Board

Pankaj Shah

TITLE
Member of Scientific Advisory Board

Gutta Rao

TITLE
Additional Director
AGE
63
TENURE
0.2 yrs

Popuri Chowdary

TITLE
Additional Director
AGE
74
TENURE
0.2 yrs

Sanjay Dave

TITLE
Additional Director
AGE
64
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess Vimta Labs's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vimta Labs has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Should You Be Excited About Vimta Labs Limited's (NSE:VIMTALABS) 15% Return On Equity?

The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Vimta Labs: 15% = ₹253m ÷ ₹1.7b (Based on the trailing twelve months to March 2019.) Most know that net profit is the total earnings after all expenses, but the concept of shareholders' equity is a little more complicated. … Does Vimta Labs Have A Good Return On Equity? … Combining Vimta Labs's Debt And Its 15% Return On Equity While Vimta Labs does have a tiny amount of debt, with debt to equity of just 0.098, we think the use of debt is very modest.

Simply Wall St -

Do You Know What Vimta Labs Limited's (NSE:VIMTALABS) P/E Ratio Means?

We'll look at Vimta Labs Limited's (NSE:VIMTALABS) P/E ratio and reflect on what it tells us about the company's share price. … Vimta Labs has a price to earnings ratio of 15.72, based on the last twelve months. … The formula for price to earnings is: Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS) Or for Vimta Labs: P/E of 15.72 = ₹180 ÷ ₹11.45 (Based on the year to March 2019.) Is A High Price-to-Earnings Ratio Good?

Simply Wall St -

Here's Why We Think Vimta Labs (NSE:VIMTALABS) Is Well Worth Watching

Check out our latest analysis for Vimta Labs How Quickly Is Vimta Labs Increasing Earnings Per Share? … So we're pleased to report that Vimta Labs insiders own a meaningful share of the business. … Vimta Labs's earnings per share growth has been so hot recently that thinking about it is making me blush.

Simply Wall St -

Why I Like Vimta Labs Limited (NSE:VIMTALABS)

Looking at the company as a whole, as a potential stock investment, I believe VIMTALABS has a lot to offer. … is a company with great financial health as well as a. … Below, I've touched on some key aspects you should know on a high level

Simply Wall St -

What Kind Of Shareholder Owns Most Vimta Labs Limited (NSE:VIMTALABS) Stock?

The big shareholder groups in Vimta Labs Limited (NSE:VIMTALABS) have power over the company. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Vimta Labs is a smaller company with a market capitalization of ₹4.3b, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Is Vimta Labs Limited's (NSE:VIMTALABS) ROE Of 15% Impressive?

Our data shows Vimta Labs has a return on equity of 15% for the last year. … One way to conceptualize this, is that for each ₹1 of shareholders' equity it has, the company made ₹0.15 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is Vimta Labs's Share Price Gain Of 242% Well Earned?

It might be of some concern to shareholders to see the Vimta Labs Limited (NSE:VIMTALABS) share price down 22% in the last month. … So while it's never fun to see a share price fall, it's important to look at a longer time horizon. … Over half a decade, Vimta Labs managed to grow its earnings per share at 41% a year.

Simply Wall St -

Should You Be Tempted To Sell Vimta Labs Limited (NSE:VIMTALABS) Because Of Its P/E Ratio?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … Based on the last twelve months, Vimta Labs's P/E ratio is 27.45. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

Boasting A 15% Return On Equity, Is Vimta Labs Limited (NSE:VIMTALABS) A Top Quality Stock?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … To keep the lesson grounded in practicality, we'll use ROE to better understand Vimta Labs Limited (NSE:VIMTALABS). … That means that for every ₹1 worth of shareholders' equity, it generated ₹0.15 in profit.

Simply Wall St -

Do Institutions Own Vimta Labs Limited (NSE:VIMTALABS) Shares?

The big shareholder groups in Vimta Labs Limited (NSE:VIMTALABS) have power over the company. … Vimta Labs is not a large company by global standards. … See our latest analysis for Vimta Labs

Simply Wall St -

Company Info

Description

Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers laboratory, analytical food and water testing and analysis, preclinical and clinical research, biological molecule structural and functional analysis, environmental assessment, and clinical reference laboratory services. Vimta Labs Limited was founded in 1984 and is based in Hyderabad, India.

Details
Name: Vimta Labs Limited
VIMTALABS
Exchange: NSEI
Founded: 1984
₹3,743,957,623
22,107,810
Website: http://www.vimta.com
Address: Vimta Labs Limited
Plot Nos. 141/2 & 142,
IDA Phase II,
Hyderabad,
Andhra Pradesh, 500051,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 524394 Equity Shares Mumbai Stock Exchange IN INR 10. Jan 2002
NSEI VIMTALABS Equity Shares National Stock Exchange of India IN INR 10. Jan 2002
Number of employees
Current staff
Staff numbers
1,081
Vimta Labs employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/15 12:54
End of day share price update: 2019/07/15 00:00
Last estimates confirmation: 2018/05/11
Last earnings filing: 2019/07/03
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.